8-K
filed November 10, 2025, 6:59 PM ET
ticker DMRA
CIK 0001800315
M&A
confidence high
sentiment neutral
materiality 0.90
Damora Therapeutics, Inc. (DMRA): M&A transaction — Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors
Damora Therapeutics, Inc.
- Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
- Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.
- Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.
- Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.
- Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Damora Therapeutics, Inc.: Filed Certificates of Designation for Series B and Series C Preferred Stock, creating new stock series with specific rights and limitations (effective 2025-11-07).
- Change
- charter amendment
- Effective
- 2025-11-07
Exact text from the filing
On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Damora Therapeutics, Inc. completed an acquisition involving Damora Therapeutics, Inc. (closed 2025-11-10).
- Action
- acquisition
- Counterparty
- Damora Therapeutics, Inc.
- Closing
- 2025-11-10
Exact text from the filing
On November 10, 2025, the Company completed its business combination with Damora.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.